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More Bad News About Anti-Inflammatory Agents
Valdecoxib (Bextra, Pfizer Inc.) joined its COX-2 inhibitor cousin, Rofecoxib (Vioxx, Merck Inc.) on the list of pharmaceuticals withdrawn from the market because of an unfavorable riskversus-benefit decision. In April 2004 the United States Food and Drug Administration (FDA) asked Pfizer to stop selling Bextra, leaving Celecoxib (Celebrex, Pfizer Inc.) as the lone remaining COX-2 inhibitor available to treat pain and inflammation. Vioxx and Bextra plummeted from their status as "wonder drugs" for arthritis sufferers earlier this year because of evidence from several randomized clinical trials demonstrating increased cardiovascular risks including myocardial infarction, unstable angina, cardiac arrest, and stroke associated with their use [1] [2] [3] . In addition, Bextra use has been reported to be associated with serious skin reactions including Stevens-Johnson syndrome, and toxic epidermal necrolysis [4] .
Non-steroidal anti-inflammatory drugs (NSAIDs) are effective treatments for inflammation, pain, and fever because they inhibit the enzyme, cyclo-oxygenase, which is responsible for synthesis of prostaglandins, major mediators of inflammation. Two isozymes of cyclo-oxygenase exist, Cyclooxygenase 1 (COX-1) and 2 (COX-2), which have different physiologic actions. COX-1 mediates inflammation and generates the prothrombotic eicosanoid, thromboxane A 2 (TXA 2 ), but also predominates in the stomach generating prostaglandins that have protective effects on gastrointestinal mucosa. COX-2 activity is increased in inflammatory states, resulting in pain and swelling, but also generates prostacyclin (PGI 2 ) which is a vasodilator and inhibitor of platelet aggregation. Because aspirin and other NSAIDs nonselectively inhibit both COX-1 and COX-2, their use is associated not only with reduced inflammation, but also gastrointestinal irritation, including mucosal bleeding and ulceration. The emergence of selective COX-2 inhibitors six years ago offered the possibility of better tolerability and fewer gastrointestinal side effects for patients suffering from severe arthritis pain. The trio of approved COX-2 inhibitors quickly climbed to rank among the top-selling prescription medications in the U.S. with yearly sales exceeding $5 billion [5] .
Aspirin has known cardiovascular protective effects by reducing TXA 2 -induced platelet activation and aggregation. In contrast, selective COX-2 inhibitors appear to be detrimental to cardiovascular health, particularly at high doses. The results of three major clinical trials as well as several observational studies have provided evidence that rofecoxib, valdecoxib, and celecoxib are associated with increased risk of major cardiovascular events. The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial [1] showed that long-term treatment with rofecoxib (50 mg/day) was associated with an increased relative risk of myocardial infarction compared to naproxen (1000 mg/day). The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial [2] was halted when an increased relative risk of cardiovascular events was identified in the rofecoxib group. And, in the most recent trial reported in March 2005, valdecoxib was associated with increased cardiovascular risk in patients undergoing coronary bypass surgery [3] .
By reducing PGI 2 formation while not affecting thromboxane A2 production, COX-2 inhibitors disrupt the homeostatic balance of these two parallel arachidonic acid pathways. This imbalance favors platelet aggregation and thrombosis, as well as hypertension. These actions of COX-2 inhibitors were recognized prior to drug marketing in 1999, and the risks of cardiovascular events associated with these agents were described shortly afterwards [6] .
However, it wasn't until September 2004 that Merck withdrew Vioxx from the market coinciding with release of the APPROVEe study findings, prompting investigators to review results of similar trials. In December 2004, the FDA required Pfizer to add a black-box warning about cardiovascular risks and skin reactions to Bextra's label [4] . Two FDA advisory panels unanimously concluded earlier this year that Bextra, Vioxx, and Celebrex increased risk of myocardial infarction and stroke. The panelists concluded that Celebrex should stay on the market because studies showed it had fewer associated adverse health effects than the other COX-2 inhibitors. The panel, however, stopped short of recommending immediate withdrawal of Bextra and Vioxx.
The FDA also made the surprising move in their sweeping announcement in April to advise manufacturers to revise label warnings (package inserts) to include cardiovascular and gastrointestinal bleeding risk for all NSAIDs including ibuprofen and naproxen, two common household over-the-counter pain relievers. This move may confuse and worry consumers. However, the FDA maintains that short-term use of NSAIDs is not associated with cardiovascular risk.
In the aftermath of the COX-2 inhibitor saga, for many the question persists of what is ailing the FDA? They wonder if the very institution whose origin more than 65 years ago stemmed from the tragedies of unregulated therapies now failed American consumers by allowing dangerous drugs to be marketed? Congressional hearings have focused on whether the FDA is too slow to respond, too lax in evaluating post-marketing safety data, or uncomfortably close to drug manufacturers. Some allege that pharmaceutical companies misrepresent the evidence of risks and benefits by failing to publish unfavorable study results [7] . Others believe that the public outcry to speed up the drug approval process and facilitate patient access to potentially life-saving new therapies has resulted in holes in the drug safety net. The FDA, in turn, claims to lack authority in enacting changes in post-marketing oversight of drugs, such as limiting advertising, restricting indications for use, mandating safety reviews, suspending availability, and withdrawing approval [7] .
How should patients be advised about the use of antiinflammatory agents? Steve Galson, acting director of the FDA's Center for Drug Evaluation and Research states that short-term use of over-the-counter products taken at recommended doses should not be a problem. People suffering from more severe arthritis pain should consult with their doctor about use of Celecoxib. Treatment with the lowest effective dose of Celecoxib for the shortest duration of time is recommended.
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